| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CDK8 protein kinase; Cell division protein kinase 8; Cyclin Dependent kinase 8; K35; Mediator complex subunit cdk8; Mediator of RNA polymerase II transcription subunit cdk8; Protein kinase K35;;CDK8 |
| WB Predicted band size | 53 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human CDK8 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于CDK8抗体的虚构参考文献示例(仅供示意，建议通过学术数据库查询真实文献)：
1. **文献名称**：*CDK8-Specific Antibodies Reveal Its Oncogenic Role in Colorectal Cancer*
**作者**：Smith J. et al.
**摘要**：研究利用特异性CDK8抗体，证明CDK8在结直肠癌中通过调控β-catenin信号通路促进肿瘤生长，提示其作为潜在治疗靶点。
2. **文献名称**：*Development of a High-Affinity Anti-CDK8 Antibody for Breast Cancer Diagnostics*
**作者**：Lee H. et al.
**摘要**：报道一种新型CDK8单克隆抗体的开发，验证其在乳腺癌组织中的高特异性表达，并探讨其作为诊断标志物的临床价值。
3. **文献名称**：*CDK8 Kinase Activity Inhibition by Neutralizing Antibodies Suppresses HIF-1α-Driven Tumor Angiogenesis*
**作者**：Garcia R. et al.
**摘要**：通过中和性CDK8抗体抑制其激酶活性，显著降低缺氧诱导因子HIF-1α介导的肿瘤血管生成，为抗肿瘤治疗提供新策略。
4. **文献名称**：*CDK8 Antibody-Based Profiling Identifies Its Association with Chemotherapy Resistance in Leukemia*
**作者**：Wang T. et al.
**摘要**：基于CDK8抗体的蛋白组学分析揭示其高表达与白血病化疗耐药性相关，机制涉及STAT1信号通路的异常激活。
**提示**：以上为模拟示例，实际文献需通过PubMed、Web of Science等平台检索关键词(如“CDK8 antibody”“CDK8 biomarker”)。
The CDK8 antibody is a crucial tool for studying the role of Cyclin-Dependent Kinase 8 (CDK8), a serine/threonine kinase within the CDK family. Unlike other CDKs involved in cell cycle regulation, CDK8 primarily modulates transcriptional processes as part of the Mediator complex, a multi-protein assembly that bridges transcription factors and RNA polymerase II. CDK8 phosphorylates transcription regulators, including components of the Mediator complex and transcription factors like STAT1. thereby influencing gene expression in pathways such as Wnt/β-catenin, HIF-1α, and p53. Dysregulation of CDK8 has been linked to cancers (e.g., colorectal, breast) and inflammatory diseases, making it a potential therapeutic target.
CDK8 antibodies are widely used in research to detect protein expression, localization, and interactions via techniques like Western blotting, immunohistochemistry, and immunoprecipitation. These antibodies are often raised in rabbits or mice, with monoclonal variants offering high specificity. Validation includes testing against CDK8-deficient cell lines to confirm absence of cross-reactivity with related kinases (e.g., CDK19). Commercially available CDK8 antibodies enable investigations into its oncogenic mechanisms, such as promoting epithelial-mesenchymal transition or chemoresistance. Ongoing studies focus on developing CDK8 inhibitors, underscoring the antibody's utility in both basic research and drug discovery.
×
